Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen

Publisher： Karger

E-ISSN： 2296-5262|37|7-8|378-383

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.7-8, 2014-05, pp. : 378-383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab with high‐dose methotrexate in primary central nervous system lymphoma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 12, 2015-12 ,pp. : 1149-1154

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients

By  

Oncology, Vol. 60, Iss. 2, 2001-02 ,pp. : 134-140

Karger

Access to resources Recommend Favorite

Primary Central Nervous System Lymphoma in the Elderly

By  

Oncology Research and Treatment, Vol. 37, Iss. 7-8, 2014-07 ,pp. : 376-377

Karger

Access to resources Recommend Favorite

Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-10 ,pp. : 179-182

Karger

Access to resources Recommend Favorite

MYC protein expression is associated with poor prognosis in primary diffuse large B‐cell lymphoma of the central nervous system

By  

APMIS (ELECTRONIC), Vol. 123, Iss. 7, 2015-07 ,pp. : 596-603

John Wiley & Sons Inc

Access to resources Recommend Favorite